Quantum Cyber N.V. Reports $5.1 Million Net Loss in Q1 2026, Shifts Focus to Pancreatic Cancer Screening

Quantum Cyber N.V., formerly known as Mainz Biomed N.V., reported its financial results for the first quarter of 2026, revealing a net loss of approximately $5.1 million, a slight increase from a net loss of $5.0 million in the same period of the previous year. The company did not generate any revenue during this quarter, consistent with its strategic shift away from its colorectal cancer screening business, which it has decided to exit in favor of focusing on pancreatic cancer screening products. The total operating expenses for the quarter were $2.5 million, down from $2.7 million in the prior year, primarily due to reduced sales and marketing expenses.

The company's total assets increased to $7.7 million as of March 31, 2026, compared to $5.3 million at the end of 2025. This growth was largely driven by a significant increase in cash reserves, which rose to $4.5 million from $0.7 million, following a successful capital raise of $6 million through preferred stock offerings and $2.1 million from the issuance of ordinary shares. The total liabilities decreased to $3.1 million from $4.7 million, reflecting the company's efforts to streamline its financial obligations.

In terms of operational changes, Quantum Cyber N.V. has undergone a significant restructuring, including the termination of its German subsidiary's employees as part of its strategic pivot. The company has also appointed new leadership, with David Lazar taking on the role of CEO and Robert Liscouski as non-executive Chairman. The decision to exit the colorectal cancer business has led to the sale of related assets, including the ColoAlert product line, which was sold for $348,966, and the NextGen intellectual property, sold for $1.25 million.

Looking ahead, the company plans to concentrate its efforts on the development and commercialization of its pancreatic cancer screening products. Despite the challenges posed by its accumulated deficit of approximately $110 million and ongoing operational losses, management believes that the current cash reserves, along with potential future financing, will be sufficient to meet its operational needs for at least the next year. However, the company acknowledges that its ability to continue as a going concern is contingent upon successfully executing its business plan and securing additional funding.